Ipilimumab is a fully human monoclonal antibody (IgG1) that promotes T-cell-mediated antitumor activity in patients with melanoma by blocking the interaction of CTLA-4 with CD80/CD86 and augmenting T-cell activation and proliferation.6,7. This evidence concerns the gene CTLA4 and melanoma.